資源描述：
《紫杉醇脂質(zhì)體與紫杉醇聯(lián)合順鉑治療非小細(xì)胞肺癌的臨床觀察.pdf》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在應(yīng)用文檔-天天文庫(kù)。
1、·50·醫(yī)藥雜志2013年6月第25卷第6期Med＆PharmJChinPLA，Vo1．25，No．61Ju．·論著·紫杉醇脂質(zhì)體與紫杉醇聯(lián)合順鉑治療tied,細(xì)胞肺癌的臨床觀察楊怡敏，錢(qián)偉華，潘迎英【摘要]目的比較紫杉醇脂質(zhì)體聯(lián)合順鉑與紫杉醇注射液聯(lián)合順鉑治療非小細(xì)胞肺癌的療效及化療毒副反應(yīng)。方法45例非小細(xì)胞肺癌隨機(jī)分為觀察組23例和對(duì)照組22例，觀察組采用紫杉醇脂質(zhì)體175mg／m靜脈滴注；對(duì)照組采用紫杉醇注射液175mg／In靜脈滴注。兩組均聯(lián)合順鉑80mg／m，21d為1周期。評(píng)價(jià)療效及化療毒副反應(yīng)。結(jié)果兩組疾病控制率差異無(wú)統(tǒng)計(jì)學(xué)意義(P>
2、0．05)，觀察組過(guò)敏反應(yīng)及3～4級(jí)骨髓抑制發(fā)生率低于對(duì)照組(P<0．05)，其余化療毒副反應(yīng)兩組之間差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0．05)。結(jié)論紫杉醇脂質(zhì)體聯(lián)合順鉑治療非小細(xì)胞肺癌，與紫杉醇相比，療效相似，而過(guò)敏反應(yīng)和骨髓抑制發(fā)生率低。[關(guān)鍵詞]紫杉醇脂質(zhì)體；紫杉醇；非小細(xì)胞肺癌；抗腫瘤聯(lián)合化療方案[中國(guó)圖書(shū)資料分類(lèi)號(hào)]R734．2；R730．53[文獻(xiàn)標(biāo)志碼]A[文章編號(hào)]2095—140X(2013)06—0050—03[DoI]10．3969／j．issn．2095—140X．2013．06．014ClinicalObservationofPacl
3、itaxelLiposomeorPaclitaxelCombinedwithCisplatininTreatmentofNon-smallCellLungCancerYANGYi—min，QIANWei—hua，PANYing—ying(DepartmentofOncology，TraditionalChineseMedicalHospitalofZhangjiagang，Jiangsu215600，China)[Abstract]ObjectiveTocompareeffectsandadversereactionsofPaclitaxellipo
4、somecombinedwithCisplatinorPaclitaxelinjectioncombinedwithCisplatinintreatmentofnon-smallcelllungcancer(NSCLC)．MethodsAtotalof45patientswithNSCLCwererandomlydividedintotherapygrouptreatedwith175mg／mpaclitaxelliposomeofintra—venousinfusionandcontrolgrouptreatedwith175mg／mPaclita
5、xelofintravenousinfusion．BothgroupswerecombinedwithCisplatin80mg／m．a(chǎn)nd1cyclewas21d．Curativeeffectandadversereactionbychemotherapywereevaluated．ResultsThedifferenceofdiseasecontrolrates(DCR)oftwogroupswasnotstatisticallysignificant(P>0．05)．Inci—denceratesofallergicreactionsandgr
6、adeⅢ～Ⅳofbonemarrowsuppressionintherapygroupweresignificantlylowerthanthoseincontrolgroup(P<0．05)，anddifferencesoftherestofadversereactionsbychemotherapyintwogroupswerenotstatisticallysignificant(P>0．05)．ConclusionPaclitaxelliposomecombinedwithCisplatinintreatmentofNSCLCmaygetsi
7、milarilyclinicaleffectwithtaxol，whileincidenceratesofallergicreactiofiandbonemarYowsuppressionarelower．[Keywords]Paclitaxelliposome；Paclitaxel；Non·small—celllungcarcinoma；Antineoplasticcombinedchemo—therapyprotocol肺癌是最常見(jiàn)的惡性腫瘤，在某些國(guó)家和地區(qū)果，現(xiàn)報(bào)告如下。已成為發(fā)病率最高的惡性腫瘤，非小細(xì)胞肺癌1資料與方法(non-small
8、celllungcancer，NSCLC)占肺癌總數(shù)的75％～80％，全球每年平均有120萬(wàn)新發(fā)病例?。1．
